Glaukos
<templatestyles src="Module:Hatnote/styles.css"></templatestyles>
Lua error in package.lua at line 80: module 'strict' not found.
| 150px | |
| Public | |
| Traded as | NYSE: GKOS |
| Industry | Health care |
| Founded | 2001 |
| Founder |
|
| Headquarters | Laguna Hills, California, United States |
|
Key people
|
Thomas Burns (President and CEO |
| Revenue |  US$45.6 million (2014) |
 US$14.1 million (loss) (2014) |
|
| Footnotes / references financial information[1] |
|
Glaukos Corporation is a glaucoma treatment company based in Laguna Hills, California.[1] Thomas Burns is Glaukos' president and CEO.[2]
Contents
Products
Glaukos developed the "iStent" titanium micro-stent. The device, which is about the width of a human hair, is implanted during cataract surgery to reduce intraocular pressure.[2] As of 2015[update], the iStent was the smallest device ever approved by the United States Food and Drug Administration.[3] The availability of the iStent led to the addition of two codes to the Current Procedural Terminology set in 2015, 0191T and 0376T.[4]
Business model
In 2015, Glaukos planned to transition from private company status to become a public company with an initial public offering (IPO) of company stock.[1] The proposed stock symbol for the company was "GKOS".[1]
Glaukos' president and chief executive officer (CEO) Thomas Burns says Glaukos was the first to develop micro-stents for the treatment of glaucoma and is well ahead of its competitors.[2] The CEO of MicroOptx, Chris Pulling, has stated that Glaukos is his "most direct" competitor.[3]
History
Founded in 2001 by Olav Bergheim, Richard Hill and Mory Gharib, the company has raised $156 million in venture funding from Versant Ventures, OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Meritech Capital Partners, Domain Associates, Fjord Capital Management and Montreux Equity Partners.[2]
The company ranked 19th on the Wall Street Journal's annual Next Big Thing list in 2011.[2]
The company ranked seventh on the Wall Street Journal's annual Next Big Thing list in 2012.[2]
In June 2012, the Food and Drug Administration approved the first iStent implant.[2]
References
- ↑ 1.0 1.1 1.2 1.3 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 3.0 3.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This corporation or company article is a stub. You can help Wikipedia by expanding it. |
